Autolus Therapeutics (AUTL) Stock: Buy, Sell, or Hold?
AUTL - Autolus Therapeutics plc American Depositary Share
$1.59
-0.04 (-2.16%)
▼
5d:
-7.85%
30d:
-18.72%
90d:
+9.31%
HOLD
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 11, 2026
19d
Get Alerted When AUTL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AUTL shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: AUTL shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: AUTL is currently trading at $1.58, which is considered oversold relative to its 30-day fair value range of $1.69 to $1.93.
Technical Outlook: Technically, AUTL is in a uptrend. The price is currently testing key support at $1.54. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AUTL scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $8.72 (+438.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AUTL is in a uptrend. The price is currently testing key support at $1.54. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AUTL scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $8.72 (+438.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.69 -
$1.93
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (70/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 438.6% below Wall St target ($8.72)
- BULLISH: Bottoming setup score 70/100 — corrected, stabilizing, and turning up
- CAUTION: Recommendation downgraded due to -7.8% 5-day decline
Trading Range Analysis
30-Day Trading Range
$1.69 -
$1.93
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.54
Resistance Level
$1.82
Current Trend
Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.54
Wall Street Target
$8.73
(+438.6%)
Revenue Growth (YoY)
118.4%
Profit Margin
-238.6%
Share & Embed Analysis
Last updated: October 22, 2026 10:43 AM ET
Data refreshes hourly during market hours. Next update: 11:43 AM
Data refreshes hourly during market hours. Next update: 11:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AUTL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 72 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 70 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 76 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 51 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 69 BUY |
